Search

Your search keyword '"Eggers Hendrik"' showing total 35 results
Start Over Author "Eggers Hendrik"
35 results on '"Eggers Hendrik"'

3. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients

Author

Steffens Sandra, Köhler Astrid, Rudolph Raphael, Eggers Hendrik, Seidel Christoph, Janssen Martin, Wegener Gerd, Schrader Mark, Kuczyk Markus A, and Schrader Andres J

Subjects
Renal cell cancer, Biomarker, C-reactive protein, Prognosis, Survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background To evaluate the prognostic significance of the pre-operative C-reactive protein (CRP) serum level in patients with renal cell cancer (RCC). Methods We evaluated 1,161 RCC patients with complete patient and tumour specific characteristics as well as information about their pre-operative CRP-level, who had undergone either radical nephrectomy or nephron-sparing surgery at two German high-volume centres (University Hospitals of Hannover and Ulm). The mean follow-up was 54 months. Results The CRP-level, stratified to three subgroups (CRP ≤ 4, 4–10, and >10 mg/l), correlated significantly with tumour stage (p 10 mg/l had a 1.67 and 2.48 fold higher risk of dying due to their RCC compared to those with a pre-operative CRP ≤4 mg/l, respectively. Conclusions A high preoperative serum CRP level is an independent predictor of poor survival in patients with RCC. Its routine use could allow better risk stratification and risk-adjusted follow-up of RCC patients.

Published
2012
Full Text
View/download PDF

4. Caveolin 1 protein expression in renal cell carcinoma predicts survival

Author

Steffens Sandra, Schrader Andres J, Blasig Hanna, Vetter Gesa, Eggers Hendrik, Tränkenschuh Wolfgang, Kuczyk Markus A, and Serth Jürgen

Subjects
Diseases of the genitourinary system. Urology, RC870-923
Abstract

Abstract Background Caveolae play a significant role in disease phenotypes such as cancer, diabetes, bladder dysfunction, and muscular dystrophy. The aim of this study was to elucidate the caveolin-1 (CAV1) protein expression in renal cell cancer (RCC) and to determine its potential prognostic relevance. Methods 289 clear cell RCC tissue specimens were collected from patients undergoing surgery for renal tumors. Both cytoplasmic and membranous CAV1 expression were determined by immunohistochemistry and correlated with clinical variables. Survival analysis was carried out for 169 evaluable patients with a median follow up of 80.5 months (interquartile range (IQR), 24.5 - 131.7 months). Results A high CAV1 expression in the tumor cell cytoplasm was significantly associated with male sex (p = 0.04), a positive nodal status (p = 0.04), and poor tumor differentiation (p = 0.04). In contrast, a higher than average (i.e. > median) CAV1 expression in tumor cell membranes was only linked to male sex (p = 0.03). Kaplan-Meier analysis disclosed significant differences in 5-year overall (51.4 vs. 75.2%, p = 0.001) and tumor specific survival (55.3 vs. 80.1%, p = 0.001) for patients with higher and lower than average cytoplasmic CAV1 expression levels, respectively. Applying multivariable Cox regression analysis a high CAV1 protein expression level in the tumor cell cytoplasm could be identified as an independent poor prognostic marker of both overall (p = 0.02) and tumor specific survival (p = 0.03) in clear cell RCC patients. Conclusion Over expression of caveolin-1 in the tumour cell cytoplasm predicts a poor prognosis of patients with clear cell RCC. CAV1 is likely to be a useful prognostic marker and may play an important role in tumour progression. Therefore, our data encourage further investigations to enlighten the role of CAV1 and its function as diagnostic and prognostic marker in serum and/or urine of RCC patients.

Published
2011
Full Text
View/download PDF

12. Anti-EGFR-Based Therapy in Recurrent or Metastatic HNSCC – What Difference Does it Make?

Author

Eggers, Hendrik, Häbel, Lea, Ganser, Arnold, Grünwald, Viktor, Merten, Roland, Warnecke, Athanasia, Durisin, Martin, and Ivanyi, Philipp

Subjects
*LUNG cancer prognosis, *THERAPEUTIC use of monoclonal antibodies, *LUNG cancer, *CONFIDENCE intervals, *EPIDERMAL growth factor receptors, *METASTASIS, *CANCER relapse, *TREATMENT effectiveness, *QUALITY assurance, *DESCRIPTIVE statistics, *PALLIATIVE treatment, *OVERALL survival, *PROPORTIONAL hazards models
Abstract

Patients with R/M HNSCC treated with palliative first-line therapy at Hannover Medical School between October 2005 and December 2016 have been included to show changes in survival following broad utilization of cetuximab. Treatment periods were defined from 10/2005 to 12/2008 (Period A) and 01/2009 to 12/2016. Overall survival did not improve over time. However, in subgroup analysis cetuximab utilized at any time vs. never showed a significant improve of overall survival (11.3 vs. 6.3 months, HR: 0.55, 95%-CI: 0.4–0.8, p = 0.04). Therefore, this study supports the application of cetuximab in this real-world population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Die Infiltration von Programmed Death 1 positiven Mononukleären Zellen und eine hohe Serum-CRP-Expression stellt eine Risikokonstellation für das Gesamtüberleben bei Patienten mit klarzelligem Nierenenzellkarzinom (kNZK) dar

Author

Steffens, Sandra, Abbas, Machmud, Schrader, Andres J., Goßhennig, Annika, Eggers, Hendrik, Becker, Jan U., Bellut, Maria, Grünwald, Viktor, and Ivanyi, Philipp

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Programmed death 1 (PD-1) ist ein T-Zell co-inhibitorischer Rezeptor. Die Bedeutung von PD-1 zu Risikoprädiktion ist Gegenstand aktueller Forschung. Hier untersuchen wir in kNZK die prognostische Bedeutung von PD-1 Expression und Serum-CRP-Spiegel im Hinblick auf das Gesamtüberleben.[zum vollständigen Text gelangen Sie über die oben angegebene URL], 65. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie

Published
2019

20. Hematologic Recovery from Venetoclax-Containing Regimens in Relapsed/Refractory Acute Myeloid Leukemia Patients Depending on Prior Allogeneic Hematopoietic Cell Transplantation

Author

Shahswar, Rabia, primary, Beutel, Gernot, additional, Klement, Piroska, additional, Rehberg, Alina, additional, Gabdoulline, Razif, additional, Koenecke, Christian, additional, Markel, Dominik, additional, Eggers, Hendrik, additional, Eder, Matthias, additional, Stadler, Michael, additional, Hambach, Lothar, additional, Ehrlich, Steve, additional, Gohring, Gudrun, additional, Schlegelberger, Brigitte, additional, Trummer, Arne, additional, Krauter, Juergen, additional, Ganser, Arnold, additional, Thol, Felicitas, additional, and Heuser, Michael, additional

Published
2019
Full Text
View/download PDF

21. FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia

Author

Shahswar, Rabia, primary, Beutel, Gernot, additional, Klement, Piroska, additional, Rehberg, Alina, additional, Gabdoulline, Razif, additional, Koenecke, Christian, additional, Markel, Dominik, additional, Eggers, Hendrik, additional, Eder, Matthias, additional, Stadler, Michael, additional, Hambach, Lothar, additional, Ehrlich, Steve, additional, Göhring, Gudrun, additional, Schlegelberger, Brigitte, additional, Dammann, Elke, additional, Reuter, Marlene, additional, Wichmann, Martin, additional, Neziri, Blerina, additional, Ganser, Arnold, additional, Thol, Felicitas, additional, and Heuser, Michael, additional

Published
2019
Full Text
View/download PDF

28. FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.

Author

Shahswar, Rabia, Beutel, Gernot, Klement, Piroska, Rehberg, Alina, Gabdoulline, Razif, Koenecke, Christian, Markel, Dominik, Eggers, Hendrik, Eder, Matthias, Stadler, Michael, Hambach, Lothar, Ehrlich, Steve, Göhring, Gudrun, Schlegelberger, Brigitte, Dammann, Elke, Reuter, Marlene, Wichmann, Martin, Neziri, Blerina, Ganser, Arnold, and Thol, Felicitas

Subjects
CYTARABINE, AZACITIDINE, LEUKEMIA, WASTE salvage
Abstract

FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia Eighty-one patients were identified that fulfilled the selection criteria of the FLAVIDA patients and were compared to the FLAVIDA patients included in this analysis (detailed information about the dosing scheme are provided in the Supplementary materials). Cumulative incidence of blood count recovery amongst responding patients in the FLAVIDA cohort (red line) and patients in the FLA-IDA control cohort (blue line). (C) Relapse-free survival of the nine patients in the FLAVIDA cohort and of the 32 patients in the FLA-IDA control cohort who achieved CR/CRi after one cycle of chemotherapy. [Extracted from the article]

Published
2020
Full Text
View/download PDF

32. GATA5CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression

Author

Peters, Inga, primary, Eggers, Hendrik, additional, Atschekzei, Faranaz, additional, Hennenlotter, Jörg, additional, Waalkes, Sandra, additional, Tränkenschuh, Wolfgang, additional, Großhennig, Anika, additional, Merseburger, Axel S., additional, Stenzl, Arnulf, additional, Kuczyk, Markus A., additional, and Serth, Jürgen, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results